idea-002 · vet · US
For use by licensed veterinarians and veterinary technicians in clinical and post-discharge settings to apply controlled sub-atmospheric pressure to open, contaminated, or free-skin-grafted distal-extremity wounds in dogs and horses, as an adjunct to standard wound management.
Finished enough to read, and waiting for you. 7 of 7 departments answered: 7 conditional, none blocking. 15 of 153 claims verified. 4 of 8 things it rests on are critical and open; the first is cheap to find out.
A wound-therapy device built for animals rather than adapted from one built for people. After a dog is degloved by a car or a horse tears open a lower leg, the wound is slow, dirty and hard to bandage; one treatment is to seal it under an airtight dressing and apply gentle suction, which draws out fluid and encourages healing. Human versions of this exist and vets already buy them off-label, but they are designed for flat, hairless skin, and the published veterinary experience is that the seal keeps failing on a furred, tapering, moving limb. This is a small single-use pump with no fluid canister, plus a dressing and adhesive drape designed specifically to hold suction on fur. There is no FDA (US Food and Drug Administration) premarket review for animal-only devices and no insurance code — the owner pays cash at the practice.
A dog degloves a hock, or a horse opens a distal limb, and the wound heals badly, slowly and expensively under a conventional bandage. Human medicine solved a version of this with negative pressure wound therapy, and veterinary practices already improvise with human single-use units off-label. The bet is that a device engineered for the actual problem — fur, a limb that moves and gets chewed, an owner managing it at home after discharge — is enough better than the improvisation that specialty and equine practices will buy it, and that an owner already paying for the surgery will pay a few hundred dollars more for the adjunct. The structural attraction is that a veterinary-only device has no FDA premarket pathway at all claim 2verified, claim 48verified, claim 49verified — no 510(k) (premarket notification), no De Novo (De Novo classification request), no IDE — so the gap between a design and first revenue is tooling and qualification rather than a submission queue. The structural danger is the same sentence read backwards: the absence of a premarket gate protects nobody, including us claim 17unconfirmed. Whatever moat exists has to be in the drape chemistry, the interface or the supply chain, because it cannot be in the regulatory calendar.
In the Wrap's one-paragraph version, written for someone who has not opened the file. Domain: canine-equine-distal-limb-wounds
This chain lacks the link a US medtech business case is normally built around. There is no payer. Not an unfavourable payer, not a missing policy: no payer at all. Read everything below against that.
The weakest link is the one everything depends on. Each dollar below is one owner's decision, once, for one case, made at a price the practice sets above its own cost. Any indemnity cheque arrives later and goes to the owner, never to the practice or the manufacturer.
What this idea rests on that is not yet known, in the order this idea's own decision queue puts it: worst if false first, cheapest to settle first inside that. The first row is open; open any other for what would settle it.
What would settle it (cheap): twenty structured calls with ACVS (American College of Veterinary Surgeons)-affiliated small-animal and equine surgeons, asking first whether they use NPWT on degloving, shearing and graft cases at all, then what unit, at what cost, and what would make them change and send the animal home with it
claim 19unconfirmed, claim 24unconfirmed, claim 25unconfirmed, claim 47unconfirmed, claim 141unconfirmed, claim 148unverified, claim 149unverified
What would settle it (cheap): structured conversations with owners at discharge from two or three referral practices, putting the choice and price as they would actually be offered, plus a human reading two pet insurers' full policy documents rather than their marketing pages and asking one insurer directly whether an invoiced NPWT line has ever been paid
claim 12unconfirmed, claim 21unconfirmed, claim 53unconfirmed, claim 55unconfirmed, claim 56unconfirmed
What would settle it (project): a limb-model rig with instrumented pressure logging, a motion cycle and a calibrated exudate load, run first against a commercial PICO dressing to reproduce the Kamus adhesion/seal failure and only then against the candidate's drape — before, not with, the fifteen-dog/fifteen-horse study written down as claim 46unconfirmed
What would settle it (project): a caseload count built from ACVS practice directories and referral volumes rather than from a prevalence estimate, priced against what a practice pays the direct-to-practice vendor today, plus two conversations with distributor category managers about terms for a first-year veterinary SKU
claim 13unconfirmed, claim 14unconfirmed, claim 15unconfirmed, claim 26unconfirmed, claim 27unconfirmed, claim 40unconfirmed, claim 139unconfirmed
What would settle it (cheap): a prior-art scan of veterinary drape and limb-interface filings, read for whether the space is already claimed or merely crowded, then provisional filings drafted against the six named live patents
What would settle it (project): counsel pulls the claim sets for the six named live US patents from USPTO (United States Patent and Trademark Office) full text — no connector here reaches claims text — and charts them against the candidate's drape, interface and connector; claims 64 and 138 between them name five of the six
claim 5verified, claim 6verified, claim 7unconfirmed, claim 64unconfirmed, claim 138unconfirmed
What would settle it (project): instrumented bench measurement of pressure at the dressing port — not at the pump — and of pump ON-time against a leak-driven duty cycle on a limb model, with fault injection against the hardware over-pressure limit, against the PS-1 design inputs as written (IR-17 claims 65 and 66 came back unconfirmed; REQ-0148 Extending manifest row… bounds claim 65unconfirmed and does not settle it)
What would settle it (cheap): a quote from one converter and one sterile-packaging house against the PS-1 pump specification and a dressing spec — REQ-0066 The pump subassembly now has a named…, open, which per IR-17 claims 65 and 66 came back unconfirmed to IR-19 claims 68 and 69 came back unconfirmed should wait for REQ-0150 Quote verbatim's standard scopes and should quote the pack at both the 7% and the 20% duty sizes, with FCC Part 15 as a separable line
claim 2verified, claim 18unconfirmed, claim 31unconfirmed, claim 41unconfirmed, claim 48verified, claim 49verified, claim 50unconfirmed, claim 52unconfirmed, claim 54unconfirmed, claim 57unconfirmed, claim 58unconfirmed, claim 60unconfirmed, claim 61unconfirmed, claim 63unconfirmed, claim 67unconfirmed, claim 68unconfirmed, claim 69unconfirmed
Each row is one thing this idea has to be true. Ordered by what a failure would cost and, inside that, by what it costs to find out — for this idea only; bands never compare between ideas.
Seven chairs, each answering from its own field. The verdict, and the first condition it set.
| Regulatory | conditional | C1 21 CFR (Title 21 of the Code of Federal Regulations) 807.81(a) conditions the 510(k) premarket notification duty on a device that is both subject to the § 807.20 registration requirement and intended for human use; a device exempt from § 807.20… +3 more condition(s) the position → |
| Clinical & Scientific | conditional | C1 A bench-plus-in-vivo seal-duration study in at least 15 dogs and 15 horses, applying the candidate's fur-compatible adhesive drape and limb-conforming interface to open or grafted distal-limb wounds… +3 more condition(s) the position → |
| Market Access | conditional | C1 No HCPCS Level II code, CPT (Current Procedural Terminology) code, or Medicare/Medicaid coverage determination can apply to a device used exclusively in veterinary medicine, because CMS (Centers for Medicare & Medicaid Services) code assignment and Medicare (Title… +2 more condition(s) the position → |
| Technology & R&D | conditional | C1 A fur-compatible adhesive drape can achieve and hold a working seal at approximately -80 mmHg (millimetres of mercury) on a canine or equine distal limb for at least 72 hours of normal ambulation — claim: 28 — would be… +10 more condition(s) the position → |
| Operations & NPI | conditional | C1 The capital-intensity estimate for reaching first revenue (claim 18unconfirmed) prices dressing tooling and sterile-barrier packaging validation but does not name — and is not shown to include — qualification… +8 more condition(s) the position → |
| Legal & IP | conditional | C1 US Patent 5,636,643 (Argenta/Morykwas, Wake Forest, filed 1993-03-09) has expired and, even if live, would not read on this device's mechanism — claim: 5 — would be settled by: python3 -m connectors… +4 more condition(s) the position → |
| Commercial | conditional | C1 The annual US caseload of canine degloving, shearing, and distal-limb wounds severe enough to warrant NPWT or free skin grafting falls in the range 30,000-80,000 cases — claim: 13 — would be settled… +8 more condition(s) the position → |
A position is not evidence: it cites the file's tags and issues none. blocks opens an impact review and kills nothing.
Only verified counts toward a score. A low count is usually a statement about the tooling — an absent data file, an unset key — rather than about the idea.
No claim on this idea has been refuted.
two, answering different questions — the score-mover is a human reading the clinical full texts; the decision-mover is queue row 1 B2 Veterinary surgeons switch from the human…, twenty structured calls with specialty surgeons.
They differ, and the difference is information: the first moves a number on the scorecard; the second decides whether there is a business.
Only verified counts toward a score. A low count is usually a statement about the tooling (an absent data file, an unset key) rather than about the idea.
Re-run 2026-09-24 against the recomputed Verified Composite above (142 claims, 14 verified, 0 refuted). Verified data only; a blank operand does not evaluate to false and is never read as a 0.
and cannot be
satisfied. **Reimbursement remains blank, and blank for the reason it has always been
blank: it has no referent.** A companion-animal device has no third-party payer for
the factor to be a fact about; revenue is owner cash-pay through the practice. That is
not a low score, not a zero, and not a missing measurement, and reading it as 0 would
kill this candidate on a condition written for human devices sold into a reimbursed
pathway.
unverifiable from market by
design, as did the equine-segment composite (claim 100unconfirmed); the 2023 price-comparison line
(claim 109unconfirmed) is unconfirmed and additionally drops "limited to low exudate-producing
wounds" from the sentence it quotes, which excludes this candidate's open and grafted
indication. The usual decomposition route is closed rather than merely unpopulated:
procedures is Medicare fee-for-service and covers no animal procedures under any
code, so no US connector can ever supply veterinary volume, and there is no Medicare
volume here that could be mistaken for a market size. **A blank TAM must not be read as
a TAM below floor.**
PATENTSVIEW_API_KEY"; that was **wrong on both
counts** — this repo's patent connector is EPO (European Patent Office) OPS, and claims 5 and 6 **verified on
2026-09-17**. US5636643 (naive term expired 2013-03-09) and US5645081 (2011-11-14) are
confirmed real and expired, and constrain nobody. That is evidence against a
block on the foundational layer, subject to the connector's stated limits (naive
20-year term, no PTA/SPC/legal-status check, no assignee field, so the "right family
member" doubt on US5645081 is narrowed rather than closed). The layer that could
actually block — live canister-free / superabsorbent and dressing-interface claims
(claim 7unconfirmed) — names no patent number and remains unsearched. The kill requires an
identified live enforceable patent covering the mechanism with no workaround; **none
has been identified in either direction**, so no auto-kill.
refuted claim? → **DOES NOT FIRE. 0 of 142 claims are
refuted.** Nothing in this file is active negative evidence. The negative findings
it carries (claims 9, 20, 37, 39 and the Kamus seal-failure line) all sit on
unconfirmed claims and pull no factor down — they are unresolved, not refuted, and a
later human read could make them either.
status: is not
set by this block.
The compound kill condition has an undefined operand for any veterinary candidate, and that is a structural mismatch rather than a property of this idea. Flagged for Stage 6 humans and for knowledge-base/rubric-proposals/. No rubric edit made, none implied, and no proposal queued — one candidate is not calibration data, and calibration-log.md is still empty.
A human reading the clinical full texts — AJVR 2022;83(10) (PMID (PubMed identifier) 35973001), Equine Vet J 2022 (PMID 34115409), and Kamus 2019 (PMID 30841889), all three now entered as claims. Their existence is confirmed; the direction and strength of their findings is not, and they bear on whether this candidate's premise survives at all. Every abstract-level signal on file is unfavourable — control wounds better on every endpoint in the Beagle pilot, no long-term advantage over calcium alginate at this candidate's exact anatomical site, and an equine PICO study that could not be completed because adhesion and seal failed. Note this cuts both ways: the negative evidence is exactly as unresolved as the positive, and nothing here licenses scoring the mechanism factor in either direction today.
This is also the cheapest open item in the file. Everything else that would move a score — the TAM components, the FTO landscape, adoption and willingness-to-pay, capital and margin — is licensed data or commissioned work costing thousands.
Every kill condition reads a verified factor score. Across Regulatory, Reimbursement, TAM and FTO — the only four factors the gate consults — this file now has two of four resolved: Regulatory at 4 and FTO at 2.
0:
the rubric's own instruction is to never conflate "we don't know yet" with "the answer is
no."
So two of the four gate operands now carry real information and both point away from a kill, while the two that would speak to whether there is a business here — is anyone paying, and how big is it — remain silent. The gate's non-kill is not a signal of merit. It says the regulatory and IP perimeter is clear and that the commercial evidence base is still too thin for the gate to have an opinion.
wrapped is not an approval — it means a human can now read this.
No human review is recorded. Shortlisting, legal and clinical sign-off and capital allocation are Tier 3: no agent in this repo makes or simulates one. The packet is wrapped, so it can be read now.
Runs only after a human shortlists the idea.
Not converged — which is not an approval either way. A blocks verdict opens an impact review; it kills nothing.
evidence-gated — read off this idea's own decision queue. A state, not a rank, and never comparable between ideas.
Click any step to see what it holds for this idea. donecurrentloopinghuman only
## Wrap section, as writtenThe packet a human reads. See docs/wrap-spec.md. This section says nothing about whether the idea is good — it says the file is finished enough to be read, and names what to do next. Filling it in advances no candidate and approves nothing.
The one-paragraph version. A wound-therapy device built for animals rather than adapted from one built for people. After a dog is degloved by a car or a horse tears open a lower leg, the wound is slow, dirty and hard to bandage; one treatment is to seal it under an airtight dressing and apply gentle suction, which draws out fluid and encourages healing. Human versions of this exist and vets already buy them off-label, but they are designed for flat, hairless skin, and the published veterinary experience is that the seal keeps failing on a furred, tapering, moving limb. This is a small single-use pump with no fluid canister, plus a dressing and adhesive drape designed specifically to hold suction on fur. There is no FDA premarket review for animal-only devices and no insurance code — the owner pays cash at the practice.
What would have to be true, quoted verbatim from each deck's load-bearing condition (all three decks rebuilt 2026-09-29):
What the business dies without — the top two rows of the assessment's decision queue (knowledge-base/assessments/idea-002.md, posture evidence-gated: 4 critical · 3 high · 1 low), quoted:
The desirability deck's condition sits inside B2 Veterinary surgeons switch from the human…. The viability deck's patent condition sits at queue row 6 as B4 No live enforceable patent reads on… (high, partial), and the feasibility deck's seal condition at row 3 as B1 The wear system holds a working seal at… (critical, project cost). The decks name what each lens most depends on; the queue ranks by exposure, then by cost.
Cheapest next test: two, answering different questions — the score-mover is a human reading the clinical full texts; the decision-mover is queue row 1 B2 Veterinary surgeons switch from the human…, twenty structured calls with specialty surgeons.
They differ, and the difference is information: the first moves a number on the scorecard; the second decides whether there is a business.
Where the evidence actually stands. wrap_status.py reports 15 of 153 claims verified — 132 unconfirmed, 6 unverified, 0 refuted — and all 15 verified claims are unstamped by evidence class. It reports 9/9 factors and 4/4 core factors accounted for; that counts the Stage 2 triage table, where every row carries a score or a named gap. The narrower verified-only count is in the Verified Composite, last recomputed 2026-09-24 against 142 claims and 14 verified: 4/9 factors under Reading A, 3/9 under Reading B, 2/4 core — below the 6/9 threshold, a research routing and not a kill. One tag has moved since that recompute claim 99verified, and the section has not been re-scored against it; that is Stage 4's work, not this section's.
What is verified is perimeter, not product: that veterinary-only manufacturers are exempt from registration claim 2verified and that 510(k) and PMA (premarket approval) attach to human-use devices claim 48verified claim 49verified; that the human analog would be Class II (FDA device class II), which the Verifier scoped to the counterfactual only claim 4verified; that the two foundational Wake Forest patents have expired claim 5verified claim 6verified; that the human NPWT special controls require an instructions-only usability test claim 99verified; that FDA's recall definitions reach devices intended for animal use claim 84verified; and that certain papers and other firms' human-use clearances exist. No commercial claim in this file has been verified. Nothing verified says whether the seal holds, how big the market is, what the unit sells for, who carries it, or whether a single veterinarian wants it.
Blocked on tooling, not on a finding — none of these is evidence that the thing is false:
market and adoption are unverifiable by design. Caseload, price, share, margin,
distribution and willingness to pay are outside the instrument, not weakly evidenced. An
empty FDA scan on this candidate is coverage absence, not competitive absence.
unconfirmed because the CPG Sec. 655.100 attribution cannot be checked here
claim 1unconfirmed, not because the exemption is in doubt — its substance is carried by
claims 2, 48 and 49.
patent connector takes one number, returns dates, and never reads claims text. It
confirmed three live Smith & Nephew patents claim 64unconfirmed and two further live
patents from Mölnlycke and Genesis claim 138unconfirmed, but the claim-chart question in
both lines is Tier 3 legal work no agent may render; and the wider landscape question cannot
be run at all, since it has no patent number to query claim 7unconfirmed. EPO_OPS_KEY
is set — the old "unset PATENTSVIEW_API_KEY" diagnosis was wrong and is closed.
| Factor | Score | Why | What would settle it |
|---|---|---|---|
| Regulatory pathway | 4 | Claims 1-3. Scored as what is actually true for a vet-only device, not as a 510(k): per CPG Sec. 655.100 there is no premarket notification or approval, so the "expected review burden" this factor measures is close to nil and…the rest of this reasoningtime-to-revenue is genuinely unblocked. The same fact cuts the other way and is scored into the 4 rather than a 5: because there is no premarket review, no predicate confers any regulatory validation — the PICO analog in the frontmatter is a design reference, not a clearance this product inherits, and there is no agency finding a customer or investor can point to. claim 3unconfirmed keeps a live post-market surface (misbranding/adulteration on labeling and claims), and claim 4verified prices the counterfactual: any human-use claim collapses this into a Class II 510(k) with the incumbent NPWT estate as backdrop. Note that the low review burden is symmetric and feeds the low Factor 5/8 scores.device_class: n/a is correct and deliberate. | FDA CPG Sec. 655.100 (CPG 7125.35) read in full from the FDA Compliance Policy Guides manual, plus FD&C Act §§ 501/502 and an FDA CVM primary page — free, human-read only, no paid source needed. |
| Reimbursement pathway | **n/a — not scored** | Claims 11, 12. Deliberately left blank, and deliberately not scored 0. There is no third-party payer for US companion-animal care in the sense this factor measures; revenue is owner cash-pay through the practice, with pet insurance…the rest of this reasoning(claim 12unconfirmed, <5% penetration) reimbursing the owner after the fact rather than paying the provider. A 0 would assert "reimbursement is bad," which is a different statement from "the concept does not apply," and it would combine with Factor 1 in the Stage 5 kill condition ("regulatory AND reimbursement both below floor 2/5") — a condition written for human devices. Blank means no referent, not a bad result. Rubric-fit gap flagged for humans; not resolved here and no rubric edit made. | The NAPHIA State of the Industry Report and an AAHA/AVMA veterinary practice-economics survey — both licensed reports a human must purchase and attach, roughly low hundreds to low thousands of dollars. |
| TAM | 2 | Claims 13, 14, 15 — all three components are Generator estimates with no primary source, and the file says so. Midpoints: ~55k qualifying canine cases × ~$250 net per unit × ~25% obtainable share ≈ $3-4M/yr initial obtainable US canine…the rest of this reasoningrevenue; even at 100% of qualifying canine cases the serviceable ceiling is ~$14M/yr before equine. The 2 reflects the size, which is small in absolute medtech terms and sits exactly at the 2/5 kill floor — the uncertainty is in the Confidence column, not the score. claim 13unconfirmed is the component most at risk and the hardest to close: no US connector covers veterinary procedure volume because no Medicare-equivalent utilization dataset exists for animals, so this may be permanently unconfirmable inside this pipeline. | VetCompass US or Banfield/Mars State of Pet Health caseload data (volume), PICO list pricing plus a Covetrus/Patterson price file (price), and ACVS/AAEP directory counts (share) — human-attached, licensed data in the low thousands of…the rest of this gap analysisdollars. |
| FTO / IP | 2 | Claims 5, 6, 7. The foundational-clearance half is the credible half: 5,636,643 (Argenta/Morykwas, Wake Forest, filed 1993-03-09) would have expired on a 20-years-from-filing basis, and the foundational NPWT estate is broadly understood to…the rest of this reasoningbe off-patent. Two problems keep this at 2. (i) The specific numbers are unreliable by the Generator's own admission — 5,645,081 is recollection, may be the wrong family member, and 5,636,643 is the only number actually found in a search, so at minimum one of the two cited patents cannot be relied on. (ii) More importantly, the dimension that could actually block this product — live Smith & Nephew PICO canister-free/superabsorbent claims and dressing-interface chemistry (claim 7unconfirmed) — has no patent number identified at all. That is not "unverified," it is unsearched. Score 2 = not known to be blocked and not meaningfully cleared either. Explicitly not an FTO-blocked auto-kill: that requires an identified live enforceable patent, and none has been identified in either direction. Scoring higher on the expired foundational patents would be a mistake, since nothing about this idea depends on those being live. | PatentsView lookups on US5636643 and US5645081 (free, once an API key is set) plus a human-commissioned FTO landscape search by patent counsel covering Smith & Nephew/BlueSky Medical/Solventum — professional searches typically run several…the rest of this gap analysisthousand dollars. |
| Moat / defensibility | 2 | Claims 16, 17, and 19. The named assets — fur-compatible drape chemistry and a chew/bandage-resistant limb interface — are real engineering problems and are the right place to look, but they are aspirational IP: nothing is filed, no…the rest of this reasoningclaim scope exists, and claim 16unconfirmed is flagged as Generator judgment. claim 17unconfirmed is the load-bearing negative and it is correct: the Factor 1 advantage is symmetric. With no premarket review, a fast-follower faces no regulatory delay at all — only tooling and distribution — so the ordinary medtech moat (a competitor's 1-3 year clearance lag) is simply absent from this business. The pump is commodity. What is left is brand, trade dress, and veterinary distribution relationships, none of which is evidenced here. claim 19unconfirmed makes it worse: if vets keep buying off-label PICO, there is nothing to defend. | A USPTO/Google Patents prior-art search on fur-compatible adhesive drape and limb-conforming NPWT interface chemistry — free via Google Patents, or a paid professional search for thoroughness. |
| Mechanism & clinical risk | 1 | claim 9unconfirmed governs and it is negative: AJVR 2022, 83(10) reports a disposable canister-free NPWT device as feasible but of inferior efficacy to conventional therapy for cutaneous wounds in dogs — the same form factor and the same target…the rest of this reasoningspecies as this product. This is not a caveat to be scored around. The product's entire premise is that the canister-free single-use format delivers NPWT's benefit in a package a practice can send home with an owner; a published comparative inferiority finding in exactly that format, in exactly that species, goes to the core of the idea. The counterweights are much weaker evidence: claim 8verified (PMID 27569833) is an uncontrolled 7-dog case series on free skin grafts, and claim 10verified (PMC6404353, PMC10458497) is equine feasibility plus a scoping review — none comparative. The underlying NPWT mechanism is not what is in doubt; the form factor is. Scored 1 rather than 0 only because the AJVR full text has not been read and its scope may be narrower than this indication (general cutaneous wounds vs. grafted distal-limb, where the 7-dog series is at least directionally positive), and "inferior efficacy" in an unread title could range from a primary-endpoint miss to a secondary difference. There is no reading of that title under which it is good news, so it cannot be scored 2+. | The AJVR 2022;83(10) full text (AVMA (American Veterinary Medical Association) Journals, may be paywalled) for design, n, and scope of the inferiority finding. |
| Capital intensity & time-to-revenue | 4 | claim 18unconfirmed, resting on claims 1-3. This is the strongest factor on the file and the real reason the candidate is interesting: no premarket submission, no IDE/IND-equivalent gate, no clinical hold, with first revenue plausibly at…the rest of this reasoninglow-single-digit millions dominated by dressing tooling, sterile packaging validation, and one or two prospective case series. Held at 4 rather than 5 for two reasons: the cost figure is an unsourced Generator estimate with no quotes behind it, and claim 9unconfirmed raises the de facto evidence burden well above what claim 18unconfirmed assumes — selling against a published inferiority finding requires comparative data, which is materially more than "one or two case series" in both dollars and calendar. Regulatory speed does not buy commercial speed when the literature is against you, so this factor is coupled to Factor 6 and should be revisited if claim 9unconfirmed verifies. | Three human-attached quotes: dressing tooling from a contract manufacturer, ISO (International Organization for Standardization) 11607 sterile-barrier validation from a packaging test lab, and a case-series protocol/budget from an ACVS-affiliated teaching hospital — each likely several…the rest of this gap analysisthousand dollars to obtain. |
| Competitive intensity | 2 | Frontmatter predicate_or_analog plus claims 8, 9, 17, 19. The competitive baseline is not an empty veterinary market: human PICO is already being bought and used off-label by exactly the target customers — that is why the canine and…the rest of this reasoningequine literature exists at all — alongside conventional canistered V.A.C. So this product does not enter a vacuum, it must displace an incumbent that is already installed, already priced, and already familiar to the surgeon. Per claim 17unconfirmed, nothing regulatory delays Smith & Nephew, Solventum/3M, or a low-cost entrant from putting a veterinary-labeled SKU into Covetrus or Patterson distribution the moment the segment looks real. claim 19unconfirmed is load-bearing for this factor and the Generator correctly flags it as a behavioral belief with no research behind it. | Covetrus/Patterson/Midwest distributor catalogs and Smith & Nephew/Solventum product materials (free to pull), plus a structured ACVS/AAEP surgeon survey — primary research, likely low five figures. |
| Strategic fit & portfolio balance | 3 | No claim in the file addresses portfolio fit, and this repo contains no portfolio thesis or capital-allocation mandate to score against, so this is a placeholder rather than an assessment. Provisional read inferred from the other factors:…the rest of this reasoningthis is a cash-generative spoke profile, not a hero bet — fast to revenue and low capital (Factor 7) against a small ceiling (Factor 3) — and it would build veterinary distribution plus animal-model wound-healing capability that transfers to a later human-indication program. The weakest strategic argument for it is that it develops almost no regulatory capability, precisely because there is no submission to make. | A written portfolio thesis / capital-allocation mandate from Tier 3 humans — no direct cost, just a decision; none exists in this repo yet. |
All eight wrap criteria are met.
Source file: knowledge-base/candidates/idea-002.md
Nothing on this page is a recommendation. Shortlist review, legal and clinical sign-off and capital allocation are human-only decisions, and no agent in this repo may make or simulate one. This is a compilation of what the candidate file says.
_shared/plain-language.md